• Integrin β3 (PTR2555) Mouse mAb
1 1

Upingbio

YP-Ab-17655-53UL

Integrin β3 (PTR2555) Mouse mAb

Integrin β3 (PTR2555) Mouse mAb

$0.00 USD
$0.00 USD
Sale Sold out
Shipping calculated at checkout.
Size
  • Reaction species: Human, Mouse,Rat
  • Gene Name: ITGB3 GP3A
  • Protein name: Integrin beta-3 (Platelet membrane glycoprotein IIIa) (GPIIIa) (CD antigen CD61)
  • Molecular weight (DA): 87kDa
  • Immunogen: Synthesized peptide derived from human Integrin β3
  • Specificity: This antibody detects endogenous levels of Integrin β3 at Human, Mouse,Rat
  • Composition: PBS, pH7.4, 50% glycerol, 0.03%Proclin 300
  • Source: Mouse,monoclonal:IgG1,Lambda
  • Dilution ratio: WB 1:500-2000 ELISA 1:5000-20000
  • Purification process: Protein G
  • Storage: -20°C/1 year
  • Other Names: Integrin beta-3 (Platelet membrane glycoprotein IIIa) (GPIIIa) (CD antigen CD61)
  • Background: integrin subunit beta 3(ITGB3) Homo sapiens The ITGB3 protein product is the integrin beta chain beta 3. Integrins are integral cell-surface proteins composed of an alpha chain and a beta chain. A given chain may combine with multiple partners resulting in different integrins. Integrin beta 3 is found along with the alpha IIb chain in platelets. Integrins are known to participate in cell adhesion as well as cell-surface mediated signalling. [provided by RefSeq, Jul 2008],
  • Function: disease:Defects in ITGB3 are a cause of Glanzmann thrombasthenia (GT) [MIM:273800]; also known as thrombasthenia of Glanzmann and Naegeli. GT is the most common inherited disease of platelets. Its inheritance is autosomal recessive. It is characterized by mucocutaneous bleeding of mild-to-moderate severity and the inability of this integrin to recognize macromolecular or synthetic peptide ligands. GT has been classified clinically into types I and II. In type I, platelets show absence of the glycoprotein IIb-IIIa complexes at their surface and lack fibrinogen and clot retraction capability. In type II, the platelets express the GPIIb-IIIa complex at reduced levels (5-20% controls), have detectable amounts of fibrinogen, and have low or moderate clot retraction capability. The platelets of GT variants have normal or near normal (60-100%) expression of dysfunctional receptors.,function:Int
View full details